About Kazal-type serine protease inhibitor domain-containing protein 1
Kazal-type serine protease inhibitor domain-containing protein 1 (KAZALD1) is a protein
from Homo sapiens identified by UniProt accession
Q96I82, 304 residues long.
MolForge cross-references it against 0 known binders and
23 disease associations.
Target properties
| Protein name | Kazal-type serine protease inhibitor domain-containing protein 1 |
|---|
| UniProt accession | Q96I82 |
|---|
| Gene | KAZALD1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 304 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (23)
Diseases linked to this target (Open Targets).
- refractive error measurement · score 0.41
- neurodegenerative disease · score 0.41
- corneal topography · score 0.38
- refractive error · score 0.34
- age at onset · score 0.28
- Myopia · score 0.28
- Abnormality of refraction · score 0.28
- intraocular pressure measurement · score 0.27
- metabolite measurement · score 0.17
- diet measurement · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96I82-F1 | alphafold | PREDICTED | 82.88 | — |
Amino-acid sequence (304 residues)
MLPPPRPAAA LALPVLLLLL VVLTPPPTGA RPSPGPDYLR RGWMRLLAEG EGCAPCRPEE CAAPRGCLAG RVRDACGCCW ECANLEGQLC DLDPSAHFYG HCGEQLECRL DTGGDLSRGE VPEPLCACRS QSPLCGSDGH TYSQICRLQE AARARPDANL TVAHPGPCES GPQIVSHPYD TWNVTGQDVI FGCEVFAYPM ASIEWRKDGL DIQLPGDDPH ISVQFRGGPQ RFEVTGWLQI QAVRPSDEGT YRCLGRNALG QVEAPASLTV LTPDQLNSTG IPQLRSLNLV PEEEAESEEN DDYY
Explore Kazal-type serine protease inhibitor domain-containing protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets